Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer



Status:Archived
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:May 2008
End Date:January 2012

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Pilot Study of MK-0752 in Combination With Tamoxifen or Letrozole in Patients With Early Stage Breast Cancer Prior to Surgery


The purpose of this research project is to study the effect of a research (investigational)
drug, MK-0752 combined with either tamoxifen or letrozole on breast cancer cells.

Tamoxifen and letrozole are standard hormone treatments used to treat breast cancers that
are positive for the estrogen receptor. However, over time the breast cancer cells can
become resistant to tamoxifen and letrozole. MK-0752 is in a class of drugs called gamma
secretase inhibitors. Gamma secretase inhibitors may play a role in reversing the
resistance to drugs such as tamoxifen and letrozole.


OBJECTIVES

To evaluate the safety and tolerability of the gamma-secretase inhibitor MK-0752 in the
pre-surgical setting in patients with early stage, estrogen receptor (ER) positive breast
cancer, in combination with tamoxifen or an aromatase inhibitor (AI).

To establish the feasibility and success of multi-laboratory collaborations in evaluating
clinical specimens and biomarker testing.

To provide preliminary data on the impact of MK-0752 on a panel of biomarkers involved in
the notch signaling pathway.


We found this trial at
1
site
Cardinal Bernardin Cancer Center at Loyola University Medical Center
2160 S. First Ave.
Maywood, Illinois 60153
888-584-7888
Cardinal Bernardin Cancer Center at Loyola University Medical Center The Cardinal Bernardin Cancer Center is...
?
mi
from
Maywood, IL
Click here to add this to my saved trials